Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels
Dronedarone is currently used for the treatment of paroxysmal and persistent atrial fibrillation (AF). Pharmacological inhibition of cardiac two-pore-domain potassium (K2P) channels results in action potential prolongation and has recently been proposed as novel antiarrhythmic strategy. We hypothesi...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 July 2012
|
| In: |
Naunyn-Schmiedeberg's archives of pharmacology
Year: 2012, Jahrgang: 385, Heft: 10, Pages: 1003-1016 |
| ISSN: | 1432-1912 |
| DOI: | 10.1007/s00210-012-0780-9 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00210-012-0780-9 Verlag, Volltext: https://link.springer.com/article/10.1007/s00210-012-0780-9 
|
| Verfasserangaben: | Constanze Schmidt, Felix Wiedmann, Patrick A. Schweizer, Rüdiger Becker, Hugo A. Katus, Dierk Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1575392097 | ||
| 003 | DE-627 | ||
| 005 | 20230427042907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180522s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00210-012-0780-9 |2 doi | |
| 035 | |a (DE-627)1575392097 | ||
| 035 | |a (DE-576)505392097 | ||
| 035 | |a (DE-599)BSZ505392097 | ||
| 035 | |a (OCoLC)1341009939 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schmidt, Constanze |e VerfasserIn |0 (DE-588)1055852174 |0 (DE-627)792733142 |0 (DE-576)411903721 |4 aut | |
| 245 | 1 | 0 | |a Novel electrophysiological properties of dronedarone |b inhibition of human cardiac two-pore-domain potassium (K2P) channels |c Constanze Schmidt, Felix Wiedmann, Patrick A. Schweizer, Rüdiger Becker, Hugo A. Katus, Dierk Thomas |
| 264 | 1 | |c 13 July 2012 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.05.2018 | ||
| 500 | |a Im Titel ist "2P" tiefgestellt | ||
| 520 | |a Dronedarone is currently used for the treatment of paroxysmal and persistent atrial fibrillation (AF). Pharmacological inhibition of cardiac two-pore-domain potassium (K2P) channels results in action potential prolongation and has recently been proposed as novel antiarrhythmic strategy. We hypothesized that blockade of human K2P channels contributes to the electrophysiological efficacy of dronedarone in AF. Two-electrode voltage clamp and whole-cell patch clamp electrophysiology was used to record K2P currents from Xenopus oocytes and Chinese hamster ovary cells. All functional human K2P channels were screened for dronedarone sensitivity, revealing significant and concentration-dependent inhibition of cardiac K2P2.1 (TREK1; IC50 = 26.7 μM) and K2P3.1 channels (TASK1; IC50 = 18.7 μM) with maximum current reduction of 60.3 and 65.5 % in oocytes. IC50 values obtained from mammalian cells yielded 6.1 μM (K2P2.1) and 5.2 μM (K2P3.1). The molecular mechanism of action was studied in detail. Dronedarone block affected open and closed channels. K2P3.1 currents were reduced in frequency-dependent fashion in contrast to K2P2.1. Mutagenesis studies revealed that amino acid residues implicated in K2P3.1 drug interactions were not required for dronedarone blockade. The class III antiarrhythmic drug dronedarone targets multiple human cardiac two-pore-domain potassium channels, including atrial-selective K2P3.1 currents. K2P current inhibition by dronedarone represents a previously unrecognized mechanism of action that extends the multichannel blocking profile of the drug. | ||
| 700 | 1 | |a Wiedmann, Felix Tobias |d 1987- |e VerfasserIn |0 (DE-588)1055852441 |0 (DE-627)792733479 |0 (DE-576)411904159 |4 aut | |
| 700 | 1 | |a Schweizer, Patrick Alexander |d 1976- |e VerfasserIn |0 (DE-588)129886254 |0 (DE-627)48277987X |0 (DE-576)297887130 |4 aut | |
| 700 | 1 | |a Becker, Rüdiger |e VerfasserIn |0 (DE-588)1032502541 |0 (DE-627)738501409 |0 (DE-576)380071061 |4 aut | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e VerfasserIn |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 700 | 1 | |a Thomas, Dierk |d 1974- |e VerfasserIn |0 (DE-588)123896258 |0 (DE-627)706465601 |0 (DE-576)29393164X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Naunyn-Schmiedeberg's archives of pharmacology |d Berlin : Springer, 1873 |g 385(2012), 10, Seite 1003-1016 |h Online-Ressource |w (DE-627)254638309 |w (DE-600)1462940-9 |w (DE-576)074531433 |x 1432-1912 |7 nnas |a Novel electrophysiological properties of dronedarone inhibition of human cardiac two-pore-domain potassium (K2P) channels |
| 773 | 1 | 8 | |g volume:385 |g year:2012 |g number:10 |g pages:1003-1016 |g extent:14 |a Novel electrophysiological properties of dronedarone inhibition of human cardiac two-pore-domain potassium (K2P) channels |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00210-012-0780-9 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00210-012-0780-9 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180522 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 123896258 |a Thomas, Dierk |m 123896258:Thomas, Dierk |d 910000 |d 910100 |e 910000PT123896258 |e 910100PT123896258 |k 0/910000/ |k 1/910000/910100/ |p 6 |y j | ||
| 998 | |g 108916618 |a Katus, Hugo |m 108916618:Katus, Hugo |d 910000 |d 910100 |e 910000PK108916618 |e 910100PK108916618 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1032502541 |a Becker, Rüdiger |m 1032502541:Becker, Rüdiger |d 910000 |d 910100 |e 910000PB1032502541 |e 910100PB1032502541 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 129886254 |a Schweizer, Patrick Alexander |m 129886254:Schweizer, Patrick Alexander |d 910000 |d 910100 |e 910000PS129886254 |e 910100PS129886254 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1055852441 |a Wiedmann, Felix Tobias |m 1055852441:Wiedmann, Felix Tobias |d 910000 |d 910100 |e 910000PW1055852441 |e 910100PW1055852441 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1055852174 |a Schmidt, Constanze |m 1055852174:Schmidt, Constanze |d 910000 |d 910100 |e 910000PS1055852174 |e 910100PS1055852174 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1575392097 |e 3009912943 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 22.05.2018","Im Titel ist \"2P\" tiefgestellt"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1575392097","title":[{"subtitle":"inhibition of human cardiac two-pore-domain potassium (K2P) channels","title":"Novel electrophysiological properties of dronedarone","title_sort":"Novel electrophysiological properties of dronedarone"}],"person":[{"role":"aut","display":"Schmidt, Constanze","roleDisplay":"VerfasserIn","given":"Constanze","family":"Schmidt"},{"display":"Wiedmann, Felix Tobias","roleDisplay":"VerfasserIn","role":"aut","family":"Wiedmann","given":"Felix Tobias"},{"family":"Schweizer","given":"Patrick Alexander","display":"Schweizer, Patrick Alexander","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Rüdiger","family":"Becker","role":"aut","display":"Becker, Rüdiger","roleDisplay":"VerfasserIn"},{"display":"Katus, Hugo","roleDisplay":"VerfasserIn","role":"aut","family":"Katus","given":"Hugo"},{"given":"Dierk","family":"Thomas","role":"aut","display":"Thomas, Dierk","roleDisplay":"VerfasserIn"}],"physDesc":[{"extent":"14 S."}],"relHost":[{"origin":[{"publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1873","publisher":"Springer","dateIssuedDisp":"1873-"}],"id":{"issn":["1432-1912"],"eki":["254638309"],"zdb":["1462940-9"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Naunyn-Schmiedeberg's archives of pharmacology","title":"Naunyn-Schmiedeberg's archives of pharmacology"}],"disp":"Novel electrophysiological properties of dronedarone inhibition of human cardiac two-pore-domain potassium (K2P) channelsNaunyn-Schmiedeberg's archives of pharmacology","note":["Gesehen am 19.10.05"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"254638309","language":["eng"],"pubHistory":["1.1873 -"],"titleAlt":[{"title":"Archives of pharmacology"},{"title":"Archiv für experimentelle Pathologie und Pharmakologie"},{"title":"Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie"},{"title":"Naunyn-Schmiedebergs Archiv für Pharmakologie und experimentelle Pathologie"},{"title":"Naunyn-Schmiedebergs Archiv für Pharmakologie"}],"part":{"issue":"10","pages":"1003-1016","year":"2012","extent":"14","text":"385(2012), 10, Seite 1003-1016","volume":"385"}}],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"13 July 2012"}],"id":{"doi":["10.1007/s00210-012-0780-9"],"eki":["1575392097"]},"name":{"displayForm":["Constanze Schmidt, Felix Wiedmann, Patrick A. Schweizer, Rüdiger Becker, Hugo A. Katus, Dierk Thomas"]}} | ||
| SRT | |a SCHMIDTCONNOVELELECT1320 | ||